Interestingly enough, YBX1 has been reported as a prognostic marker for poor outcome and chemotherapy efficacy in colorectal cancer, breast cancer, nasopharyngeal carcinoma, and many other cancers.43, 44, 45. This evidence concerns the gene YBX1 and nasopharyngeal carcinoma.